Azenta (NASDAQ:AZTA – Get Free Report) and Precipio (NASDAQ:PRPO – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership.
Valuation and Earnings
This table compares Azenta and Precipio”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Azenta | $668.82 million | 2.16 | -$164.17 million | ($2.42) | -13.05 |
| Precipio | $18.53 million | 1.59 | -$4.29 million | ($1.19) | -15.33 |
Volatility and Risk
Azenta has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Precipio has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations for Azenta and Precipio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Azenta | 1 | 3 | 2 | 0 | 2.17 |
| Precipio | 1 | 0 | 0 | 0 | 1.00 |
Azenta currently has a consensus price target of $35.75, indicating a potential upside of 13.24%. Given Azenta’s stronger consensus rating and higher possible upside, equities analysts plainly believe Azenta is more favorable than Precipio.
Institutional and Insider Ownership
99.1% of Azenta shares are held by institutional investors. Comparatively, 10.5% of Precipio shares are held by institutional investors. 10.6% of Azenta shares are held by insiders. Comparatively, 16.9% of Precipio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Azenta and Precipio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Azenta | -18.45% | 1.35% | 1.13% |
| Precipio | -8.48% | -15.00% | -10.21% |
Summary
Azenta beats Precipio on 10 of the 14 factors compared between the two stocks.
About Azenta
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
About Precipio
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
